Janux Therapeutics Inc Forecast, price target & analysts
Janux Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Janux Therapeutics Inc Classifications & Recommendation:
Janux Therapeutics Inc Price Target
| Target Price | $54.57 |
| Price | $13.65 |
| Potential |
299.78%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Janux Therapeutics Inc 2027 .
The average Janux Therapeutics Inc target price is $54.57.
This is
299.78%
register free of charge
$210.00
1,438.46%
register free of charge
$29.29
114.58%
register free of charge
|
|
| A rating was issued by 26 analysts: 24 Analysts recommend Janux Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2027 of
299.78%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.59 | 10.26 |
| 31.06% | 3.12% | |
| EBITDA Margin | -913.98% | -1,585.60% |
| 3.98% | 73.48% | |
| Net Margin | -651.46% | -1,198.89% |
| 9.70% | 84.03% |
19 Analysts have issued a sales forecast Janux Therapeutics Inc 2025 . The average Janux Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Janux Therapeutics Inc EBITDA forecast 2025. The average Janux Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Janux Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Janux Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.28 | -2.05 |
| 3.03% | 60.16% | |
| P/E | negative | |
| EV/Sales | negative |
21 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Janux Therapeutics Inc...
Current Janux Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Clear Street |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Clear Street:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 25 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
